

# Gianluca Baio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9247091/publications.pdf>

Version: 2024-02-01

99  
papers

4,509  
citations

136950

32  
h-index

114465

63  
g-index

105  
all docs

105  
docs citations

105  
times ranked

7396  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. <i>British Journal of Psychiatry</i> , 2014, 205, 436-442.	2.8	325
2	Spatial and spatio-temporal models with R-INLA. <i>Spatial and Spatio-temporal Epidemiology</i> , 2013, 4, 33-49.	1.7	267
3	Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. <i>International Journal of Epidemiology</i> , 2011, 40, 712-718.	1.9	262
4	Spatial and spatio-temporal models with R-INLA. <i>Spatial and Spatio-temporal Epidemiology</i> , 2013, 7, 39-55.	1.7	233
5	The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 96351-96358.	1.8	203
6	Designing a stepped wedge trial: three main designs, carry-over effects and randomisation approaches. <i>Trials</i> , 2015, 16, 352.	1.6	176
7	The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. <i>British Journal of Ophthalmology</i> , 2012, 96, 1162-1167.	3.9	141
8	Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. <i>BMJ Open</i> , 2016, 6, e011666.	1.9	126
9	Long-term persistence with antihypertensive drugs in new patients. <i>Journal of Human Hypertension</i> , 2002, 16, 439-444.	2.2	120
10	Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. <i>Lancet Psychiatry</i> , 2020, 7, 865-874.	7.4	120
11	A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. <i>Health Technology Assessment</i> , 2014, 18, 1-226, v-vi.	2.8	116
12	Sample size calculation for a stepped wedge trial. <i>Trials</i> , 2015, 16, 354.	1.6	114
13	Stepped wedge randomised controlled trials: systematic review of studies published between 2010 and 2014. <i>Trials</i> , 2015, 16, 353.	1.6	113
14	The association between psychological stress and miscarriage: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 1731.	3.3	111
15	Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. <i>BMJ</i> , 2014, 349, g5293-g5293.	6.0	106
16	A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. <i>Clinical Therapeutics</i> , 2002, 24, 1347-1357.	2.5	96
17	Bayesian hierarchical model for the prediction of football results. <i>Journal of Applied Statistics</i> , 2010, 37, 253-264.	1.3	92
18	Probabilistic sensitivity analysis in health economics. <i>Statistical Methods in Medical Research</i> , 2015, 24, 615-634.	1.5	88

#	ARTICLE	IF	CITATIONS
19	An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2015, 33, 355-366.	3.3	83
20	Estimating weekly excess mortality at sub-national level in Italy during the COVID-19 pandemic. <i>PLoS ONE</i> , 2020, 15, e0240286.	2.5	65
21	A Review of Methods for Analysis of the Expected Value of Information. <i>Medical Decision Making</i> , 2017, 37, 747-758.	2.4	63
22	Socioeconomic variation in uptake of colonoscopy following a positive faecal occult blood test result: a retrospective analysis of the NHS Bowel Cancer Screening Programme. <i>British Journal of Cancer</i> , 2012, 107, 765-771.	6.4	56
23	Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care. <i>Schizophrenia Research</i> , 2011, 129, 104-110.	2.0	55
24	Five questions to consider before conducting a stepped wedge trial. <i>Trials</i> , 2015, 16, 350.	1.6	52
25	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. <i>Value in Health</i> , 2020, 23, 734-742.	0.3	51
26	Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out. <i>European Journal of Cancer</i> , 2018, 103, 267-273.	2.8	49
27	Uptake of Bowel Scope (Flexible Sigmoidoscopy) Screening in the English National Programme: the first 14 months. <i>Journal of Medical Screening</i> , 2016, 23, 77-82.	2.3	46
28	Economic Burden of Human Papillomavirus-Related Diseases in Italy. <i>PLoS ONE</i> , 2012, 7, e49699.	2.5	46
29	Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study. <i>BMJ Open</i> , 2015, 5, e007382-e007382.	1.9	43
30	Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity. <i>Neurology</i> , 2019, 92, e1773-e1785.	1.1	37
31	Cost-effectiveness and affordability of community mobilisation through women's groups and quality improvement in health facilities (MaiKhanda trial) in Malawi. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 1.	1.5	35
32	Estimating the expected value of partial perfect information in health economic evaluations using integrated nested Laplace approximation. <i>Statistics in Medicine</i> , 2016, 35, 4264-4280.	1.6	34
33	Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study. <i>Value in Health</i> , 2015, 18, 956-968.	0.3	33
34	Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 11.	1.5	32
35	Value of Information: A Tool to Improve Research Prioritization and Reduce Waste. <i>PLoS Medicine</i> , 2015, 12, e1001882.	8.4	31
36	Comparison of computer-assisted planning and manual planning for depth electrode implantations in epilepsy. <i>Journal of Neurosurgery</i> , 2016, 124, 1820-1828.	1.6	31

#	ARTICLE	IF	CITATIONS
37	R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. Value in Health, 2019, 22, 575-579.	0.3	31
38	Preformulated implementation intentions to promote colorectal cancer screening: A cluster-randomized trial.. Health Psychology, 2014, 33, 998-1002.	1.6	30
39	Diagnosis and management of polycystic ovary syndrome in the UK (2004â€“2014): a retrospective cohort study. BMJ Open, 2016, 6, e012461.	1.9	29
40	Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data. Statistics in Medicine, 2015, 34, 2334-2352.	1.6	28
41	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Medical Decision Making, 2020, 40, 314-326.	2.4	28
42	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis, 2011, 217, 479-485.	0.8	26
43	Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group. Clinical Therapeutics, 2015, 37, 156-167.e4.	2.5	26
44	Urinary ATP as an indicator of infection and inflammation of the urinary tract in patients with lower urinary tract symptoms. BMC Urology, 2015, 15, 7.	1.4	25
45	Methods for population adjustment with limited access to individual patient data: A review and simulation study. Research Synthesis Methods, 2021, 12, 750-775.	8.7	25
46	Incidence and prevalence of diabetes and cost of illness analysis of polycystic ovary syndrome: a Bayesian modelling study. Human Reproduction, 2018, 33, 1299-1306.	0.9	24
47	Efficient Monte Carlo Estimation of the Expected Value of Sample Information Using Moment Matching. Medical Decision Making, 2018, 38, 163-173.	2.4	23
48	Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression. Medical Decision Making, 2019, 39, 347-359.	2.4	23
49	Bayesian Cost-Effectiveness Analysis with the R package BCEA. Use RI, 2017, , .	0.2	22
50	Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases. Medical Care, 2012, 50, 1076-1085.	2.4	18
51	Modeling outcomes of soccer matches. Machine Learning, 2019, 108, 77-95.	5.4	18
52	Summarising salient information on historical controls: A structured assessment of validity and comparability across studies. Clinical Trials, 2020, 17, 607-616.	1.6	18
53	Evidence of bias in the Eurovision song contest: modelling the votes using Bayesian hierarchical models. Journal of Applied Statistics, 2014, 41, 2312-2322.	1.3	17
54	A feasibility randomised controlled trial of extended brief intervention for alcohol misuse in adults with mild to moderate intellectual disabilities living in the community; The EBI-LD study. Trials, 2017, 18, 216.	1.6	17

#	ARTICLE	IF	CITATIONS
55	A full Bayesian model to handle structural ones and missingness in economic evaluations from individual-level data. <i>Statistics in Medicine</i> , 2019, 38, 1399-1420.	1.6	17
56	Telomere length in human blastocysts. <i>Reproductive BioMedicine Online</i> , 2014, 28, 624-637.	2.4	16
57	Using epidemiological evidence to forecast population need for early treatment programmes in mental health: a generalisable Bayesian prediction methodology applied to and validated for first-episode psychosis in England. <i>British Journal of Psychiatry</i> , 2021, 219, 383-391.	2.8	16
58	Conflating marginal and conditional treatment effects: Comments on "Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study". <i>Statistics in Medicine</i> , 2021, 40, 2753-2758.	1.6	16
59	Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 260-269.	1.9	15
60	A Novel Method to Value Real Options in Health Care: The Case of a Multicohort Human Papillomavirus Vaccination Strategy. <i>Clinical Therapeutics</i> , 2013, 35, 904-914.	2.5	15
61	Effectiveness of an intervention to facilitate prompt referral to memory clinics in the United Kingdom: Cluster randomised controlled trial. <i>PLoS Medicine</i> , 2017, 14, e1002252.	8.4	15
62	Cost-Effectiveness of Enhancing Adherence to Therapy with Blood Pressure-Lowering Drugs in the Setting of Primary Cardiovascular Prevention. <i>Value in Health</i> , 2013, 16, 318-324.	0.3	14
63	Bayesian models for cost-effectiveness analysis in the presence of structural zero costs. <i>Statistics in Medicine</i> , 2014, 33, 1900-1913.	1.6	14
64	A dynamic Bayesian Markov model for health economic evaluations of interventions in infectious disease. <i>BMC Medical Research Methodology</i> , 2018, 18, 82.	3.1	14
65	Value of Information Analysis in Models to Inform Health Policy. <i>Annual Review of Statistics and Its Application</i> , 2022, 9, 95-118.	7.0	14
66	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. <i>Health Policy</i> , 2005, 74, 304-313.	3.0	13
67	Variable selection in covariate dependent random partition models: an application to urinary tract infection. <i>Statistics in Medicine</i> , 2016, 35, 1373-1389.	1.6	13
68	Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. <i>Health Economics (United Kingdom)</i> , 2017, 32, 1077-1094.	1.7	13
69	A comparative review of variable selection techniques for covariate dependent Dirichlet process mixture models. <i>Canadian Journal of Statistics</i> , 2017, 45, 254-273.	0.9	12
70	Approaches to the Estimation of the Local Average Treatment Effect in a Regression Discontinuity Design. <i>Scandinavian Journal of Statistics</i> , 2016, 43, 978-995.	1.4	11
71	Statistical Modeling for Health Economic Evaluations. <i>Annual Review of Statistics and Its Application</i> , 2018, 5, 289-309.	7.0	11
72	Calculating the Expected Value of Sample Information Using Efficient Nested Monte Carlo: A Tutorial. <i>Value in Health</i> , 2018, 21, 1299-1304.	0.3	11

#	ARTICLE	IF	CITATIONS
73	The Effects of Model Misspecification in Unanchored Matching-Adjusted Indirect Comparison: Results of a Simulation Study. <i>Value in Health</i> , 2020, 23, 751-759.	0.3	11
74	A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes. <i>Pharmacoeconomics</i> , 2009, 27, 645-655.	3.3	9
75	Development and evaluation of a manual for extended brief intervention for alcohol misuse for adults with mild to moderate intellectual disabilities living in the community: The EBI-€LD study manual. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2017, 30, 42-48.	2.0	9
76	Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy. <i>Pharmacoeconomics</i> , 2017, 35, 163-176.	3.3	9
77	Object-oriented influence diagram for cost-effectiveness analysis of influenza vaccination in the Italian elderly population. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 293-301.	1.4	8
78	Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 257-268.	1.8	8
79	Economic Evaluation of a Bayesian Model to Predict Late-Phase Success of New Chemical Entities. <i>Value in Health</i> , 2007, 10, 377-385.	0.3	7
80	Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study. <i>BMJ Open</i> , 2012, 2, e000736.	1.9	7
81	An Introduction to Handling Missing Data in Health Economic Evaluations. , 2016, , 73-85.		6
82	When Simple Becomes Complicated: Why Excel Should Lose its Place at the Top Table. <i>Global &amp; Regional Health Technology Assessment</i> , 2017, 4, grhta.5000247.	0.1	6
83	A Bayesian parametric approach to handle missing longitudinal outcome data in trial-based health economic evaluations. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2020, 183, 607-629.	1.1	6
84	&lt;p&gt;Impact of Being Eligible for Type 2 Diabetes Treatment on All-Cause Mortality and Cardiovascular Events: Regression Discontinuity Design Study&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 569-577.	3.0	6
85	Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. <i>Pharmacoeconomics</i> , 2022, , 1.	3.3	6
86	Extended brief intervention to address alcohol misuse in people with mild to moderate intellectual disabilities living in the community (EBI-ID): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 114.	1.6	5
87	Bayesian modelling for binary outcomes in the regression discontinuity design. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2019, 182, 983-1002.	1.1	5
88	A comparative review of network meta-analysis models in longitudinal randomized controlled trial. <i>Statistics in Medicine</i> , 2019, 38, 3053-3072.	1.6	4
89	BCEAweb: A User-Friendly Web-App to Use BCEA. <i>Use RI</i> , 2017, , 153-166.	0.2	3
90	Handling manipulated evidence. <i>Forensic Science International</i> , 2007, 169, 181-187.	2.2	2

#	ARTICLE	IF	CITATIONS
91	Communication of personalised disease risk by general practitioners to motivate smoking cessation in England: A cost-effectiveness and research prioritisation study. <i>Addiction</i> , 2021, , .	3.3	2
92	Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2003, 3, 227-236.	1.4	1
93	Erratum to "Spatial and spatio-temporal models with R-INLA" [Spat Spatio-tempor Epidemiol 4 (2013) 33-49]. <i>Spatial and Spatio-temporal Epidemiology</i> , 2013, 7, 37.	1.7	1
94	Transparency or Proper Study Valuation Procedures Missed?. <i>Medical Care</i> , 2013, 51, 374-378.	2.4	1
95	A predictable outcome. <i>Significance</i> , 2015, 12, 11-13.	0.4	1
96	A Bayesian nonparametric model for white blood cells in patients with lower urinary tract symptoms. <i>Electronic Journal of Statistics</i> , 2016, 10, .	0.7	1
97	Probabilistic Sensitivity Analysis Using BCEA. <i>Use RI</i> , 2017, , 93-152.	0.2	0
98	Bayesian Analysis in Health Economics. <i>Use RI</i> , 2017, , 1-22.	0.2	0
99	Regression discontinuity designs for time-to-event outcomes: An approach using accelerated failure time models. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 0, , .	1.1	0